In the PD-1 inhibitor plus chemo group, most adverse events were at grade 1–2; meanwhile, the main grade 3–4 hematological adverse events included leukopenia (13.2%), neutropenia (13.2%), anemia (5.3%), and thrombopenia (2.6%). Here, PDCD1 is linked to anemia.